Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy
Clinical trial NCT00928330 · COMPLETED
Trial details
- NCT number
- NCT00928330
- Sponsor
- Genentech, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2009-07-01
- Primary completion
- 2014-01-01
- Enrollment
- 57
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.